Drug Makers’ 340B Overcharging Must Be Addressed, House E&C Democrat Dingell Says During Hearing

Rep. Debbie Dingell (D-MI) headshot
Drug manufacturers’ conditions on 340B pricing when covered entities use contract pharmacies “need to be addressed moving forward,” U.S. Rep. Debbie Dingell (D-Mich.) said during a recent hearing.

Drug manufacturers’ decisions to impose conditions on 340B pricing when covered entities use contract pharmacies “need to be addressed moving forward,” U.S. Rep. Debbie Dingell (D-Mich.) said last week during an Energy & Commerce (E&C) health subcommittee hearing last week.

Read More »

Lilly Announces Fourth Round of Refunds for 340B Overcharges in 2019

Lilly wordmark building-mounted sign
Lilly for the fourth time this year has announced refunds for overcharges on 340B-purchased drugs during 2019.

For the fourth time this year, drug manufacturer Lilly has announced refunds for overcharges on 340B-purchased drugs during 2019.

The U.S. Health Resources and Services Administration (HRSA) posted the notice, dated May 27, on the Office of Pharmacy Affairs website

Read More »

Novo Nordisk, Sanofi, and Feds Trade Arguments in 340B Contract Pharmacy Litigation

Federal Appeals Court courtroom interior
Novo Nordisk and Sanofi urged a federal appeals court in Philadelphia to reverse a district judge’s ruling that their denials on 340B pricing when providers use multiple contract pharmacies violate the 340B statute.

Drug manufacturers Novo Nordisk and Sanofi last month urged a federal appeals court to reverse a district judge’s ruling that the companies’ conditions on 340B pricing when providers use multiple contract pharmacies violate the 340B statute.

Meanwhile, the federal government

Read More »

340B Sales Were $38.8 Billion in 2020, PhRMA-Funded Study Finds

Image of BRG 340B program white paper title page
Prescription drugs sales at 340B prices were $38.8 billion in 2020, a new PhRMA-funded study says.

Prescription drugs sales at 340B prices were $38.8 billion in 2020, “more than three times the level of 340B sales compared to just five years prior,” new drug industry funded research shows.

Total sales would have been $93.6 billion if

Read More »

Breaking News

In Important Ruling, Federal Appeals Court Says Health Center May Challenge 340B Patient Definition’s Legality

Genesis Health Care exterior sign and building
A federal appeals court says South Carolina health center Genesis Healthcare has the right to challenge the 340B patient definition's legality in a lower federal court.

A federal appeals court ruled unanimously this morning that a South Carolina health center has the right to challenge the legality of the government’s 340B patient definition in a lower federal court. The case ultimately could have profound implications for

Read More »

Breaking News

Bausch Health Announces 340B Contract Pharmacy Restrictions on All Covered Entities

Bausch Health wordmark seen through eyeglass lens
Bausch Health has imposed conditions on 340B pricing when all covered entity types—hospitals and grantees alike—use contract pharmacies.

Bausch Health this afternoon became the 18th drug manufacturer to impose conditions on 340B pricing when covered entities use contract pharmacies. The restrictions apply to all entities; there is no exemption for federal grantees.

According to Bausch’s announcement, effective Aug.

Read More »

House Appropriators Ask Feds to Use “Any Available Measures” to Curb Pharma’s 340B Pricing Denials

U.S. House Appropriations Committee room
The U.S. House Appropriations Committee says HRSA should use "any available means" to hold drug makers accountable for curtailing "use of 340B drugs in contract pharmacies."

The U.S. House Appropriations Committee said this week it is concerned about the growing number of drug manufacturers “that curtail the use of 340B drugs in contract pharmacies.” It encouraged the U.S. Health Resources and Services Administration to use “any

Read More »

As UCB Reviews HRSA’s 340B Enforcement Letter, Grassley Presses OIG for Answers

Sen. Chuck Grassley (R-IA) speaking in a meeting with hospital employees
U.S. Sen. Chuck Grassley (R-Iowa), after meeting with 340B hospital employees in his home state, tweeted that he needs answers about drug company 340B violations and actions HHS may take.

Drug manufacturer UCB says it is reviewing Monday’s letter from the U.S. Health Resources and Services Administration telling the company its restrictions on 340B pricing to covered entities that use contract pharmacies break federal law and must end immediately.

“At

Read More »

Sponsor Halts California Bill to Shield 340B Providers from Manufacturers and PBMs’ Actions

California State Sen. Richard Pan (D) speaking to a large assembly
California state Sen. Richard Pan (D) asked a state Assembly committee to cancel a hearing on his Senate-approved bill to prohibit drug manufacturer conditions on 340B pricing and pharmacy benefit manager discrimination against 340B covered entities.

A bill in California to prohibit drug manufacturer conditions on 340B pricing and pharmacy benefit manager discrimination against 340B covered entities died in a state Assembly committee on Tuesday.

The state Senate voted 24-9 to pass the bill, SB-939, on

Read More »

AHA Tells HHS It Wants Prompt Repayment for All Years Hospitals’ Medicare Drug Payments Have Been Cut

American Hospital Association seal on interior office wall
The American Hospital Association and other major hospital groups have placed multiple 340B program goals on their 2024 advocacy agendas.

The American Hospital Association wants to discuss with U.S. Health and Human Services Secretary Xavier Becerra how 340B hospitals should be promptly repaid “for all of the years (2018-2022) in which the Centers for Medicare & Medicaid Services (CMS) illegally

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report